What is ADMA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.32B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ADMA?

P/E (TTM) is 13.69 and 52-week range is $7.21 to $20.46 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ADMA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ADMA?

The company profile lists revenue (TTM) near $515M, net income (TTM) near $170M, EPS (TTM) near $0.71 when available from the market-data feed. Figures are informational and may lag live markets.

Where is ADMA Biologics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Ramsey, New Jersey, US, 231.8M shares outstanding, ISIN US0008991046 when available from company profile and filing metadata.

Chartloom

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 647 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Employees

647

Website

www.admabiologics.com/

IPO

2013-10-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)